EVOCLIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EVOCLIN (EVOCLIN).
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, blocking peptide bond formation.
| Metabolism | Primarily hepatic metabolism via CYP3A4 to active and inactive metabolites; also undergoes some renal clearance. |
| Excretion | Primarily hepatic metabolism; renal excretion of unchanged drug accounts for approximately 10% of elimination. Biliary/fecal excretion accounts for <2%. |
| Half-life | Terminal elimination half-life is approximately 15 hours (range 10-25 hours) following topical application, allowing for twice-daily dosing. |
| Protein binding | Approximately 90-95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 1.0-1.5 L/kg, indicating distribution into total body water and some tissue binding. |
| Bioavailability | Systemic bioavailability following topical application is low, approximately 1-2%, due to minimal percutaneous absorption. |
| Onset of Action | Clinical effect (reduction in inflammatory lesions) typically observed within 2-4 weeks of twice-daily application. |
| Duration of Action | Duration of action persists for the dosing interval (12 hours) with sustained effects over the course of therapy; maximal effect seen at 12 weeks. |
EVOCLIN (clindamycin phosphate) foam 1%: Apply once daily to affected area(s) of the face, shoulders, chest, and back.
| Dosage form | AEROSOL, FOAM |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | For pediatric patients 12 years and older: same as adult dosing. Safety and efficacy in children under 12 years have not been established. |
| Geriatric use | No specific dose adjustment; use caution due to potential for age-related hepatic or renal dysfunction. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EVOCLIN (EVOCLIN).
| Breastfeeding | Clindamycin is excreted in human milk; M/P ratio 0.2–1.1. Potential for GI disturbances (diarrhea, bloody stools) and sensitization in breastfed infants. Use with caution; monitor infant for diarrhea or rash. |
| Teratogenic Risk | Clindamycin (active ingredient) is Pregnancy Category B; animal studies show no fetal harm, but no adequate human studies. First trimester: minimal risk, but use only if clearly needed. Second/third trimester: no known teratogenic effects; avoid in preterm labor due to rare risk of pseudomembranous colitis in neonates. |
■ FDA Black Box Warning
Clindamycin can cause severe and sometimes fatal colitis, including pseudomembranous colitis, due to Clostridium difficile overgrowth.
| Serious Effects |
Hypersensitivity to clindamycin or lincomycin; history of antibiotic-associated colitis.
| Precautions | Risk of Clostridium difficile-associated diarrhea (CDAD); may cause severe hypersensitivity reactions; use with caution in patients with gastrointestinal disease, hepatic impairment, or renal impairment; prolonged use may result in superinfection. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal signs of pseudomembranous colitis (diarrhea, abdominal cramps). No specific fetal monitoring required; standard prenatal care. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Clinical data insufficient. |